What Changed for Bispecifics This Year?
This year’s dataset is less about early signals, more about delivery. 96% of abstracts were clinical, with most tied to trial data – giving a far clearer read on what’s working and what isn’t.
The analysis strips away the volume and leaves you with structured, decision-ready insight you can act on immediately.
Highlights from this year’s report:
- Clinical expansion: 168 trials represented, a 27% increase YoY
- Late-stage progress: Phase 3 activity has nearly doubled
- Target focus: PD‑L1 (+62.5%) and EGFR (+37.5%) gain traction alongside CD3 and PD‑1
- Solid tumours dominate with 30 abstracts (+50% YoY)
- Proven biology still leads: Established target pairs continue to dominate late-stage pipelines
Download the report to read the full story.
You May Also Be Interested In…
Learn More About Bispecific
What is Beacon Bispecific?
- The Most Comprehensive Way to Search the Bispecific Drug Development Landscape: Unique search ontologies based on Bispecific drug and trial characteristics
- Market Leading Approach to Bispecific Preclinical & Clinical Data Curation: Manual curation of key Bispecific research and development data points Bispecific research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Bispecific company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
